Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Get Free Report) have received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $38.25.
A number of analysts have recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a research report on Tuesday, May 5th. Wall Street Zen cut NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Ascendiant Capital Markets increased their price target on NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Zacks Research upgraded NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Friday, May 8th.
Check Out Our Latest Report on NRx Pharmaceuticals
NRx Pharmaceuticals Stock Performance
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. The business had revenue of $1.07 million during the quarter, compared to analyst estimates of $19.43 million. On average, equities research analysts predict that NRx Pharmaceuticals will post -0.3 EPS for the current year.
Hedge Funds Weigh In On NRx Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bleakley Financial Group LLC bought a new position in NRx Pharmaceuticals during the 4th quarter valued at $318,000. Anson Funds Management LP boosted its stake in NRx Pharmaceuticals by 26.2% during the 3rd quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock valued at $6,683,000 after purchasing an additional 420,129 shares in the last quarter. AdvisorShares Investments LLC boosted its stake in NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after purchasing an additional 78,339 shares in the last quarter. State Street Corp boosted its stake in NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after purchasing an additional 10,700 shares in the last quarter. Finally, Commonwealth Equity Services LLC bought a new position in NRx Pharmaceuticals during the 4th quarter valued at $994,000. 4.27% of the stock is owned by institutional investors.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.
Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.
Featured Articles
- Five stocks we like better than NRx Pharmaceuticals
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
